Progress of targeted therapy in multiple myeloma
10.3760/cma.j.issn.1009-9921.2018.03.001
- VernacularTitle:多发性骨髓瘤生物靶向治疗研究进展
- Author:
Quande LIN
1
;
Baijun FANG
;
Yongping SONG
Author Information
1. 450008,郑州大学附属肿瘤医院 河南省肿瘤医院血液科 河南省血液病研究所
- Keywords:
Multiple myeloma;
Biological targeted therapy;
Drug therapy
- From:
Journal of Leukemia & Lymphoma
2018;27(3):129-134
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM), the second malignancy of the hematological system, is still untreatable. With the continuous advent of novel targeted therapies, new treatment strategies for MM patients altered, response rate and mitigation depth have also been greatly improved. At the 59th American Society of Hematology (ASH) Annual Meeting, a number of bio-targeted therapies for MM were updated, especially with the combination of various new agents and cell biology therapy. Combined with reports in the 59th ASH Annual Meeting, this paper summarizes the progress of targeted therapy in MM.
